Skip to main content
Premium Trial:

Request an Annual Quote

Life Science Insights Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis, Acuity Pharmaceuticals Cand5, and Mirus Online Store

Premium

Life Science Insights said it has published “Worldwide Therapeutic RNAi 2004-2014 Forecast and Analysis,” an analysis of the RNAi-based drugs market.

According to the company, the report includes an overview of RNAi technologies and a 10-year market forecast.

“The RNAi therapeutic market will grow to over $10 billion by 2014 if the first few RNAi therapies are successful in human clinical trials, which will start later this year,” Life Science Insights senior research editor Zachary Zimmerman said in a statement released this week.


Acuity Pharmaceuticals said earlier this month that it has already begun a phase I trial of its siRNA-based age-related macular degeneration drug Cand5.


Mirus has recently launched an online store.

All of the Mirus’ reagent products, including its TransIt nucleic acid delivery and Label It nucleic acid labeling technologies, can now be purchased on the company’s website.

Additional information can be found at http://www.mirusbiocorporation.com/Merchant2/merchant.mv?Screen=SFNT&Store_Code=MBC.

 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.